Amicus Q4 Revenue Beats on Galafold; BioMarin $4.8B Deal
Amicus Therapeutics posted Q4 revenue growth on strong Galafold and Pombiliti sales, surpassing consensus estimates, but its adjusted earnings per share fell short of projections. The company agreed to be acquired by BioMarin in a $4.8 billion cash transaction.
1. Q4 Financial Results
Amicus Therapeutics reported Q4 revenue beat estimates driven by product sales, but its adjusted EPS missed consensus due to higher R&D and SG&A expenses.
2. Product Sales Performance
Galafold sales rose significantly year-over-year, contributing to the revenue beat, while Pombiliti volumes also increased, reflecting expanded patient uptake in key markets.
3. Acquisition by BioMarin
BioMarin agreed to acquire Amicus in a $4.8 billion cash deal, valuing the company at a premium and expected to close in mid-2026 after regulatory approvals.
Related News
GOOG
Meta’s 10% and Intuit’s 17% Layoffs Drive Confidence Low as Google’s AI Edge Is Questioned
GOOG•
GOOGL
Google and Blackstone Form $5B AI Cloud JV for 500MW Capacity by 2027
GOOGL•
MWC
Micware Co. Soars 51.5% in IPO Debut, Raises $22.8M
MWC•
NBIS
Nebius to Deploy 328 MW Bloom Energy Fuel Cells for AI Infrastructure
NBIS•
TNL
Travel + Leisure Co. Declares $0.60 Per Share Cash Dividend Payable June 30
TNL•
Sources
FZ